NasdaqGM:IOVABiotechs
Iovance Biotherapeutics (IOVA) Rises 16.8% on Strong Amtagvi Sales and Promising Lifileucel Data—What's Next?
Iovance Biotherapeutics recently reported third-quarter 2025 results, highlighting US$67.46 million in revenue and an improved gross margin driven by increased demand for Amtagvi, alongside the release of interim Phase 2 data for lifileucel showing a 25.6% objective response rate in advanced nonsquamous non-small cell lung cancer.
This dual update signals expanding utilization of the company’s therapies across both commercial markets and clinical trial settings, with further potential...